Background: We compared the impact of cobalt-based bare metal stents (BMSs) versus drug-eluting stents (DESs) on six-month clinical and angiographic outcomes for the single vessel intervention. Methods: All 234 patients (59.8 yrs, male 67 %) of successfully revascularized with a bare metal stent (n=38, 66.3 yrs, male 63.2 %) or a drug-eluting stent (n=196, 66.7 yrs, male 61.2 %) were enrolled. All patients received aspirin, clopidogrel and/or cilostazol as the antiplatelet regimen. Six-month angiographic and clinical outcomes were evaluated. Results: Total 234 coronary arteries were treated with 196 DESs (44.9 % Sirolimus-eluting stents; 43.9 % Paclitaxel-eluting stents; 11.2 % Zotarolimus-eluting stents) or 38 BMSs. Baseline clinical, demographic or angiographic characteristics were well balanced between the two groups. There was one in-hospital death in DES group. At six-month follow-up, angiography showed that in-stent diameter stenosis and late loss were greater in BMS group than DES group (Table). However, there were no significant differences in major adverse cardiac events (MACE) and ischemia-driven TLR/TVR rates between the two groups (Table). Conclusion: Although six-month angiographic results appear more favorable in DES group than BMS group, DES and cobalt-chromium BMS implantation in large coronary arteries show equally favorable six-month clinical outcomes.